KUKJEON PHARMACEUTICAL Co.,Ltd
Financials
Valuation Metrics
KUKJEON PHARMACEUTICAL Co.,Ltd's Market Cap is ₩1163B. At end of 2025 it was ₩1817B. Ranked #1155 of 2,436 in KR market (top 47%), #598 of 1,649 on KOSDAQ (top 36%), #136 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 116.34B KRW | KR#1,155/2,436 Sec#136/234 |
| Revenue | 127.43B KRW | KR#1,257/2,436 Sec#76/234 |
| Net Income | -8.25B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 188.79B KRW | KR#1,315/2,436 Sec#99/234 |
| Net Assets | 107.87B KRW | KR#1,343/2,436 Sec#108/234 |
| Employees | 175 | KR#1,183/2,436 Sec#98/234 |
| Value | ||
| P/B | 1.08x | KR#1,531/2,436 Sec#100/234 |
| P/S | 0.91x | KR#1,312/2,436 Sec#74/234 |
| FCF Yield | 6.44% | KR#768/2,436 Sec#38/234 |
| Profitability | ||
| ROE | -7.64% | KR#1,834/2,436 Sec#140/234 |
| ROA | -4.37% | KR#1,858/2,436 Sec#140/234 |
| Op. Margin | -0.02% | KR#1,596/2,436 Sec#113/234 |
| Revenue Growth | -9.44% | KR#1,855/2,436 Sec#172/234 |
| Earnings Growth | -528.51% | KR#1,636/2,436 Sec#109/234 |
| Financial Health | ||
| Debt Ratio | 175.01% | KR#1,485/2,436 Sec#171/234 |
| Total Debt | 39.48B KRW | KR#1,078/2,436 Sec#77/234 |
| FCF | 7.49B KRW | KR#792/2,436 Sec#48/234 |
| Cash | 11.11B KRW | KR#1,615/2,436 Sec#123/234 |
| Current Ratio | 1.32x | KR#1,450/2,436 Sec#154/234 |
| Dividend | ||
| Div. Yield | 0.44% | KR#1,299/2,436 Sec#85/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -45.58% | KR#2,015/2,436 Sec#180/234 |
| 1M Return | -4.65% | KR#1,438/2,436 Sec#134/234 |
| From 52W High | -64.08% | KR#1,914/2,436 Sec#160/234 |
| 1Y MDD | -67.51% | KR#1,820/2,436 Sec#153/234 |
| Trading | ||
| Volume | 103,020 shares | KR#851/2,436 Sec#75/234 |
| Foreign Own. | 1.46% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -156 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,975 KRW | KR#2,033/2,436 Sec#169/234 |
Company Info
Kukjun Pharm, established in 1995 and listed on KOSDAQ in 2020, is a chemical total solution company. Utilizing chemical synthesis technology, it produces active pharmaceutical ingredients (APIs), OLED materials, semiconductor materials, and secondary battery electrolyte additives, operating in both pharmaceutical and material business sectors. The company is conducting Phase 1 clinical trials for an Alzheimer's treatment with Shaperon and Phase 3 clinical trials for a combination treatment with TH Pharm, and constructed a factory in Eumseong-gun in 2023 for the commercial production of materials for AI semiconductor processes. Kukjun Pharm is headquartered in Anyang-si, Gyeonggi-do.